3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Investor Presentation (August 2026)
51 slides from 3b Blackbio Dx's investor presentation, Aug 13, 2026
Slide 1: Cover letter to BSE
(Formerly – Kilpest India Limited) Ref. No.P-66/2026-27/27 August 13, 2026 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemi
Slide 2: Investor Presentation August 2026
Since 1972 Investor Presentation August, 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Financial Highlights – Consolidated – Q1 2026-27
Financial Highlights – Consolidated – Q1 2026-27 Q1 2025-26 3,349.08 Q1 2026-27 2,223.46 14.76 1,586.35 1,321.95 10.48 1,264.45 897.84 Revenue from Operations Profit Before Tax Profit After Tax EPS Consolidated (In ₹ Lakhs) Q1 2025-26 Q1 2026-27 Revenue from Operations 2,223.46 3,349.08 Profit Befor
Slide 5: Financial Highlights – Consolidated excl. Coris – Q1 2026-27
Financial Highlights – Consolidated excl. Coris – Q1 2026-27 2,486.24 Q1 2025-26 2,223.46 Q1 2026-27 1,791.76 1,586.35 1,367.66 1,264.45 14.76 15.96 Revenue from Operations Profit Before Tax Profit After Tax EPS Consolidated (in ₹ Lakhs) Q1 2025-26 Q1 2026-27 Revenue from Operations ₹2,223.46 ₹2,486
Slide 6: Key Highlights – Agrochemicals Division
Key Highlights – Agrochemicals Division Main Thrust Area of R&D ❑ Development of novel formulations for agriculture and public health which are less harmful and cost effective. ❑ Performance monitoring of existing products/process. ❑ Improvement in existing products/process with a customer driven ap
Slide 7: Agrochemicals - Existing Products
Agrochemicals - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 •
Slide 8: Selected as part of Select 200 Companies
3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist.
Slide 9: Financial Highlights: Molecular Diagnostics (MDx) Division Q1 2026-27
Financial Highlights: Molecular Diagnostics (MDx) Division Q1 2026-27
Slide 10: Overview – MDx Division
Overview – MDx Division ❑ Founded: November 2010 | 15 years in molecular diagnostics ❑ Core Focus: Design, Development & Manufacture of Molecular Diagnostic Kits: • qPCR Assays (TRUPCR®) • Lateral Flow Assays (TRURAPID®) • NGS Assays (TRUNGS®) • Digital PCR Assays (TRUdPCR®) ❑ Product Portfolio: 120
Slide 11: Overview – MDx Division
Overview – MDx Division Well Established PAN-India & Comprehensive Brand Global Presence Molecular Diagnostics Only company to have Product & customer support Well established molecular qPCR Assays, Lateral Flow access available to over diagnostics (MDx) brand Tests and NGS assays 1,000 labs / hospi
Slide 12: Journey at a Glance
1 2 JOURNEY AT A GLANCE @ C) @ 2011-2013 %& Founded as a Lifesciences company %® Initiated R&D in Molecular Diagnostics 6 C) @ 2014-2016 % Entry into Molecular Diagnostics with Launch TRUPCR® of TRUPCR?® MDx Kits in Infectious Diseases & Oncology Portfolio 5 wf 2017-2018 & Received FMPCCI Outstandin
Slide 13: Our Strategic Priorities
Our Strategic Priorities Market Penetration: Portfolio Expansion: We aim to boost sales with current Leveraging our R&D strengths, we customers and channel partners by continuously evolve our portfolio – with expanding the range of products within new assays in qPCR, Lateral flow their existing port
Slide 14: MDx Growth Canvas excluding Coris
MDx Growth Canvas excluding Coris 3,125.0 2,142.1 842.8 952.1 668.3 608.5 625.0 505.2 153.6 125.0 111.9 76.5 ₹ Millions 25.0 5.0 1.0
Slide 15: MDx Growth Canvas including Coris
MDx Growth Canvas including Coris 3,125.0 2,142.1 1,311.2 842.8 668.3 608.5 625.0 505.2 153.6 125.0 111.9 76.5 ₹ Millions 25.0 5.0 1.0
Slide 16: Dx Business – Financials Highlights – Q1 2026-27
Dx Business – Financials Highlights – Q1 2026-27 3,205.73 * 1,619.43 ** 1,996.06 1,466.54 Q1 2025/26 Q1 2026/27 Q1 2025/26 Q1 2026/27 Revenue from Operations EBITDA 1,591.51 1,269.61 1,321.94 897.85 Q1 2025/26 Q1 2026/27 Q1 2025/26 Q1 2026/27 PBT PAT In ₹ Lakhs * In above numbers, CORIS sales of ₹86
Slide 17: MDx Business – Financials Highlights excl. Coris
MDx Business – Financials Highlights excl. Coris Q1 2026-27 2,342.90 1,818.82 1,996.06 17.4% 1,619.43 12.5% Q1 2025/26 Q1 2026/27 Q1 2025/26 Q1 2026/27 Revenue from Operations EBITDA 1,367.65 1,791.75 1,591.51 12.5% 1,269.61 7.7% Q1 2025/26 Q1 2026/27 Q1 2025/26 Q1 2026/27 PBT PAT In above numbers,
Slide 18: Business Outlook – MDx (2026-27)
Business Outlook – MDx (2026-27) Market Overview & Growth Outlook ⮚ The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹500–600 Cr. ⮚ We hold approximately 15% market share, positioning us among the market leaders. ⮚ The MDx industry is projected to g
Slide 19: Business Outlook – Dx (Q1 2026-27)
Business Outlook – Dx (Q1 2026-27) We closed Q1 2026-27 with revenue from operations of ₹3,205.73 Lakh compared to ₹1,996.06 Lakh in Q1 2025-26. This includes consolidated sales from TRUPCR Europe Limited, Manchester of ₹ 542.91 Lakh and sales from Coris BioConcept SRL, Belgium of ₹862.83 Lakh. In Q
Slide 20: Future Growth Strategy
Future Growth Strategy To continue our growth journey and to ward off seasonal spikes in coming years, we are putting following efforts: ❑ Marketing: Participating in multiple international events such as ADLM, USA (28th – 30th Jul’26) to capture more of the USA and LATAM markets. We are participati
Slide 21: Sales Model – MDx (Q1 2026-27 – 3B India)
Sales Model – MDx (Q1 2026-27 – 3B India) The company operates through three primary sales models in India: ❑ Tender Sales: This accounts for approximately 5% - 7% of the total sales and it depends on type of tender, etc. ❑ Contractual / Reagent Rental Model: In this model, we provide molecular diag
Slide 22: Our Footprints in India
Our Footprints in India Head Office & Manufacturing Site Corporate Office – Delhi Sales Office - Mumbai Sales & Marketing Team Distributor Network
Slide 23: Our Global Presence
Our Global Presence We have widespread acceptance globally with our presence now in over 70 countries spanning across Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada). Now we are expanding in Africa through strategic partnerships with channel partners.
Slide 24: Business Outlook – International
Business Outlook – International ❑ Global Expansion: Appointed new channel partners to strengthen international presence. ❑ Territorial Growth: Added customers in existing and new markets across Europe, Africa, and APAC. ❑ Regulatory Progress: Completed product registrations in several countries; on
Slide 25: Exports – Past Trend & Near-Term Vision
Exports – Past Trend & Near-Term Vision Our exports have grown substantially over the past few years. We recorded a growth in exports of 38% for Q1 2026/27 versus Q1 2025/26. This growth would have been slightly higher, had there been favorable conditions due to the ongoing geo political tensions. S
Slide 26: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site In Q1 2026-27, TRUPCR® Europe Limited (TPE) has recorded a growth of 13% in Sales as shown below versus Q1 2025-26. TRUPCR® Europe Limited continues to be a strong growth driver for the group with its “Made in UK” portfolio gaining steady acceptance across Eu
Slide 27: Events & Conferences – ADLM 2026
Events & Conferences – ADLM 2026 Our strong international presence is reinforced through active participation in global conferences, where we showcase our products and introduce new verticals. These events are key to engaging stakeholders, building partnerships, and expanding global awareness. Our p
Slide 28: Events & Conferences - International
Events & Conferences - International We continue to strengthen our global outreach and brand visibility through participation in leading international diagnostic platforms, including WHX Expo 2026 in Johannesburg. These strategic engagements provide opportunities to showcase the Company’s expanding
Slide 29: Performance Review
PERFORMANCE REVIEW ❑ As we had completed the acquisition of Coris on 29th August 2025 and according to the Ind AS rules, we can only consolidate from the date of acquisition. Therefore, this is the first year for Q1 numbers being consolidated versus previous year (not consolidated). ❑ Coris has rece
Slide 30: Future Outlook
FUTURE OUTLOOK ❑ We expect AMR products to grow at 15-20% for 2026-27 and the other products to de-grow due to Chinese competition. Overall, in 2026-27, we expect the sales to grow at 10-15% with slight positive EBITDA. Although, the geo-political situation is affecting sales, we still expect to ach
Slide 31: EU IVDR Certification
EU IVDR Certification On track towards IVDR certification of our product portfolio • Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) was published on 5 April 2017, repealing Directive 98/79/EC and introducing a strengthened regulatory framework applicable from 26 May 2026. • 3
Slide 32: Our Certifications
Our Certifications ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 40 key assays are CE-IVD marked post new IVDR regulations
Slide 33: What Sets us Apart
What Sets us Apart ❑ Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available ❑ Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 70+ countries ❑ Well experienced, strong and well retained R&
Slide 34: Our R&D Strengths
Our R&D Strengths ❑ Our well retained R&D team of scientific professionals including Ph.Ds. and M.Scs. brings vast experience in molecular diagnostics, assay design, and bioinformatics which reflects a stable, motivated workforce committed to scientific excellence and long-term innovation. ❑ This is
Slide 35: Comprehensive Panels for Syndromic Testing
Comprehensive Panels for Syndromic Testing The COVID-19 pandemic has underscored the importance of multiplex PCR TRUPCR® Flu Panel with RSV Detection Kit assays and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesse
Slide 36: Antimicrobial Resistance – A Silent Pandemic
Antimicrobial Resistance – A Silent Pandemic Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the "silent pandemic" due to its gradual and insidious nature. Image Source: AMR Action Fund ❑ Encouraging judicious use of anti
Slide 37: Solutions by 3B - to combat Antimicrobial Resistance
Solutions by 3B - to combat Antimicrobial Resistance We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR). TRUPCR® have both singlex and multiplexing RT-PCR assays for the detec
Slide 38: TRURAPID – Rapid Tests for AMR
Solutions by 3B - to combat Antimicrobial Resistance We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti- Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment: ⮚ TRURAPID® RESIST-5 OKNVI Rapid Test (For
Slide 39: Fungal Pathogens – The Overlooked Threat
Fungal Pathogens – The Overlooked Threat Invasive and superficial fungal infections are an increasingly recognized global health burden, fueled by growing immunocompromised populations, rising antifungal resistance, and persistent diagnostic delays from slow, low- sensitivity culture methods. Fungal
Slide 40: Newly Launched Solutions by 3B - to combat Fungal Pathogens
Newly Launched Solutions by 3B - to combat Fungal Pathogens TRUPCR® Skin and Nail Fungus Panel Kit (Real-Time PCR assay for qualitative detection of fungal DNA associated with skin and nail infections) TRUPCR® Aspergillus Detection & Differentiation Kit (Real-Time PCR based detection of Aspergillus
Slide 41: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We have started getting some traction for the TRUNGS® assays from the customers however, it is very low. The NGS market is at a very nascent stage and is divided in Whole Genome Sequencing, Whole Exome Sequencing, NIPT etc. With the TRUNGS® vertical, our main inten
Slide 42: Digital PCR
Digital PCR Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting-edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving needs
Slide 43: Automated Extraction System
Automated Extraction System We are trying to offer automated extraction systems to our customers. Our team alongwith VGT’s team has invested considerable time and effort into identifying an automated extraction system that meets the growing needs of our customers. With this new addition, we are conf
Slide 44: Long Term Contracts
Long Term Contracts Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitig
Slide 45: Utilization of Funds / Existing & Utilized Capacity
Utilization of Funds During the last 2 years, we have evaluated several companies in the IVD space, however, the valuations were high due to demand from diagnostic companies based on Covid profits. Also, the Sales & EBITDA were not matching our IRR or future growth possibility, hence we did not proc
Slide 46: 3B for CSR
3B for CSR Army Wives Welfare Association or AWWA for short is an association that works for the welfare of the spouses, children and dependents of Army personnel. The aim of AWWA therefore is to support and augment the official welfare efforts within the Indian Army, focusing primarily on the wel-
Slide 47: 3B for CSR
3B for CSR Sightsavers is an international organisation that works in more than 30 countries to eliminate avoidable blindness, and fight for the rights & needs of people with disability. Sightsavers’ work in India has enabled thousands of people to lead lives of independence and dignity. “3B” has be
Slide 48: 3B for CSR
3B for CSR Prerna Sewa Trust, Bhopal, has been serving poor patients at Hamidia Hospital, Bhopal for decades through daily meals, free medicines, medical equipment, and support for treatment of serious ailments. In line with our CSR commitment, 3B has been supporting the Trust by funding medical aid
Slide 49: 3B for CSR
3B for CSR Cachar Cancer Hospital & Research Centre is committed to providing affordable and accessible cancer care to patients across Northeast India, particularly serving economically disadvantaged communities. The centre has received national and international recognition for its impactful work,
Slide 50: Recognitions & Awards
Recognitions & Awards Received the “Outstanding Received the “National Received the “Outstanding Achievement Award” in MSME Award – 2018” by Achievement Award” in recognition of excellence in Hon’ble President of India on recognition of excellence in R&D through technology by 11th May 2018 under MSM
Slide 51: Jai Hind
JAI HIND 2B BlackBio Dx Ltd.